troriluzole
Phase 3- Indications
- Spinocerebellar ataxia, Obsessive compulsive disorder
Company intelligence / Profile preview
Fox Chase Therapeutics Discovery (formerly Fox Chase Chemical Diversity Center) provides medicinal chemistry, chemical biology, ADME characterization, pharmacological screening, and translational research services. The company specializes in early-stage drug/probe discovery for academic groups and non-profits. It has contributed to multiple preclinical candidates across infectious diseases including antifungals and anti-parasitic agents. Notably supported by NIH SBIR grants with over $39M awarded since inception.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fox Chase Therapeutics Discovery.